Lorcaserin
Lorcaserin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C. In addition, it is known to target 5-hydroxytryptamine receptor 2B and 5-hydroxytryptamine receptor 2A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| belviq xr extended release | New Drug Application | 2016-07-25 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 5 | 2 | 3 | 2 | 2 | 14 |
| Weight loss | D015431 | — | — | — | — | 3 | 1 | 2 | 6 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 3 | 1 | — | 4 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | 2 | 1 | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 3 | — | — | 3 |
| Dyslipidemias | D050171 | — | — | — | — | 3 | — | — | 3 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | 3 | — | — | 3 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | 1 | — | 1 | 2 |
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | — | 1 | — | 1 | 2 |
| Seizures | D012640 | — | G40.4 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 1 | 1 |
| Drug resistant epilepsy | D000069279 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lorcaserin |
| INN | lorcaserin |
| Description | Lorcaserin is a benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine substituted at position 1 by a methyl group and a t position 6 by a chloro group. It has a role as an appetite depressant and an anti-obesity agent. It is an organochlorine compound and a benzazepine. |
| Classification | Small molecule |
| Drug class | serotonin receptor agonists, primarily 5-HT2 |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1CNCCc2ccc(Cl)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 616202-92-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL360328 |
| ChEBI ID | 65353 |
| PubChem CID | 11658860 |
| DrugBank | DB04871 |
| UNII ID | 637E494O0Z (ChemIDplus, GSRS) |
Target
Agency Approved
HTR2C
HTR2C
Organism
Homo sapiens
Gene name
HTR2C
Gene synonyms
HTR1C
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2C
Protein synonyms
5-HT-1C, 5-HT1C, 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled, 5-hydroxytryptamine receptor 1C, serotonin 5-HT-1C receptor, serotonin 5-HT-2C receptor, Serotonin receptor 2C
Uniprot ID
Mouse ortholog
Htr2c (15560)
5-hydroxytryptamine receptor 2C (Q5WRU6)
Alternate
HTR2B
HTR2B
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Lorcaserin – Arena Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,185 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,876 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use